MK 5172 administered as ascending doses ranging from 100-800 mg/day in male patients with chronic genotype 1 or 3 hepatitis C virus

Trial Profile

MK 5172 administered as ascending doses ranging from 100-800 mg/day in male patients with chronic genotype 1 or 3 hepatitis C virus

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Nov 2011

At a glance

  • Drugs Grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 23 Nov 2011 New trial record
    • 08 Nov 2011 Results presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top